Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05968326 · ClinicalTrials.gov registry record · Phase 2
A Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Participants With Resected PDAC
A Phase 2 study of Adenocarcinoma, Pancreatic Ductal, sponsored by Genentech.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 260
- Enrollment target
- 20
- Study locations
NCT05968326: Recruiting Phase 2 study of Adenocarcinoma, Pancreatic Ductal, sponsored by Genentech.
NCT05968326 is a Phase 2 study of Adenocarcinoma, Pancreatic Ductal that is actively recruiting participants, run by Genentech. The registered enrollment target is 260 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (95% higher). The trial reports 20 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05968326, a Phase 2 study of Adenocarcinoma, Pancreatic Ductal, is actively recruiting participants, sponsored by Genentech.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 260 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the efficacy and safety of adjuvant autogene cevumeran plus atezolizumab and modified leucovorin, 5-fluorouracil (5-FU), irinotecan, and oxaliplatin (mFOLFIRINOX) versus mFOLFIRINOX alone in participants with resected pancreatic ductal adenocarcinoma (PDAC) who have not received prior systemic anti-cancer treatment for PDAC and have no evidence of disease after surgery.
Conditions Studied
Interventions
- DRUG Atezolizumab
- DRUG mFOLFIRINOX
- DRUG Autogene cevumeran
Study Locations (20)
California
- USC Norris Comprehensive Cancer Center - Los Angeles
- USC Norris Cancer Center - Newport Beach
- University of California, San Francisco (UCSF) - San Francisco
- University of California Los Angeles - Santa Monica
Connecticut
- St. Francis Hospital and Medical Center - Hartford
- Smilow Cancer Center - New Haven
- Yale Cancer Center - New Haven
- Smilow Cancer Hospital Care Center at Trumbull - Trumbull
New Jersey
- Memorial Sloan Kettering Cancer Center Basking Ridge - Basking Ridge
- Memorial Sloan Kettering Cancer Center - Middletown
- Memorial Sloan Kettering Cancer Center at Bergen - Montvale
Massachusetts
- Harvard Medical School - Massachusetts General Hospital (MGH) - Cancer Center - Boston
- Boston Medical Center (BMC) - Cancer Care Center - Boston
New York
- Memorial Sloan Kettering Cancer Center - Commack - Commack
- Memorial Sloan Kettering Cancer Center at Westchester - Harrison
Illinois
- Northwestern Memorial Hospital - Chicago
Indiana
- Indiana University Health Melvin & Bren Simon Cancer Center - Indianapolis
Kentucky
- University of Kentucky Medical Center - Lexington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 260 participants |
| Start Date | 2023-10-18 |
| Est. Completion | 2031-01-01 |
| Phase | Phase 2 |
What NCT05968326 shows while recruiting
NCT05968326 is an interventional study that assigns participants to a tested intervention. The registered 260 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (95% higher).
The record links to 1 condition, with Adenocarcinoma, Pancreatic Ductal appearing as the primary indexed condition, and to 3 interventions - of which Atezolizumab is the first listed.
NCT05968326 names 20 study sites across 10 states, led by California, Connecticut, New Jersey.
Frequently Asked Questions
What is clinical trial NCT05968326 about?
NCT05968326 is a clinical study titled "A Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Participants With Resected PDAC". The purpose of this study is to evaluate the efficacy and safety of adjuvant autogene cevumeran plus atezolizumab and modified leucovorin, 5-fluorouracil (5-FU), irinotecan, and oxaliplatin (mFOLFIRINOX) versus mFOLFIRINOX alone in participants with resected pancreatic ductal adenocarcinoma (PDAC) w...
What is the current status of trial NCT05968326?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 260 participants. The study started on 2023-10-18. Estimated completion is 2031-01-01.
What conditions does trial NCT05968326 study?
This clinical trial studies the following conditions: Adenocarcinoma, Pancreatic Ductal.
What interventions are being tested in trial NCT05968326?
The interventions under investigation include: Atezolizumab (DRUG), mFOLFIRINOX (DRUG), Autogene cevumeran (DRUG).
Who is sponsoring clinical trial NCT05968326?
This trial is sponsored by Genentech, which has 332 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05968326 being conducted?
This trial has 20 study locations across California, Connecticut, Illinois, Indiana, Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05968326's enrollment target sits among peer trials
260 210th of 2000 higher than 1,790 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02283996 · 260 participants · Phase 4
Adhesive Capsulitis: Prospective Analysis of Efficacy and Financial Impact for Use of Physical Therapy in Treatment
- NCT03276793 · 260 participants · NA
Brain Connectivity in Depression
- NCT03407469 · 260 participants
Measurement of Adherence and Health-Related Quality of Life, and Health-Care Resource Utilization
- NCT03713125 · 260 participants · NA
Executive Function in Early Childhood
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI